Results 161 to 170 of about 304,792 (298)

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane   +43 more
wiley   +1 more source

When co-management fails: a review of theory and lessons learned from reservoir fisheries in dry-zone of Sri Lanka [PDF]

open access: yes
Over recent decades co-management has become an increasingly popular form of governance reform in many developing countries. Viewed as a means of promoting sustainable and equitable management of natural resources, it has seen wide application in small ...
Murray, F.
core  

The economic viability of small-scale fisheries

open access: yes, 2017
Small-scale fisheries (SSF) provide food and jobs for millions of people worldwide and therefore contribute to the wellbeing of many coastal communities. However, there is concern that the benefits they generate may dwindle to nothing because they are currently threatened by overfishing, climate change, industrialization and global market shifts.
openaire   +1 more source

Clinical Validation of Plasma p‐217tau in Neurological Diseases

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi   +13 more
wiley   +1 more source

Assessing information-sharing networks within small-scale fisheries and the implications for conservation interventions. [PDF]

open access: yesR Soc Open Sci, 2021
Arlidge WNS   +6 more
europepmc   +1 more source

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold   +12 more
wiley   +1 more source

Between uncertainty and hope: Young leaders as agents of change in sustainable small-scale fisheries. [PDF]

open access: yesAmbio, 2022
Espinoza-Tenorio A   +10 more
europepmc   +1 more source

CSF Monoamine Metabolites and Cognitive Trajectory in Early Parkinson's Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Imaging and postmortem studies indicate that abnormalities in monoaminergic neurotransmission contribute to cognitive impairment in Parkinson's disease (PD). However, it remains uncertain if cerebrospinal fluid (CSF) monoamine metabolites can serve as biomarkers of cognitive decline in early PD.
Jing‐Yu Shao   +7 more
wiley   +1 more source

Editorial: Marine protected areas and small-scale fisheries

open access: yesAquaculture and Fisheries, 2020
Karim Erzini
doaj   +1 more source

Home - About - Disclaimer - Privacy